Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases
The current therapies based on immunosuppressant or new biologic drugs often show some limitations in term of efficacy and applicability, mainly because of their inadequate targeting and of unwanted adverse reactions they generate. To overcome these inherent problems, in the last decades, innovative...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/3/707 |
id |
doaj-973be7164eb546648b84626dc7864c36 |
---|---|
record_format |
Article |
spelling |
doaj-973be7164eb546648b84626dc7864c362021-03-24T00:00:40ZengMDPI AGCells2073-44092021-03-011070770710.3390/cells10030707Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory DiseasesLaura Talamini0Eiji Matsuura1Luisa De Cola2Sylviane Muller3CNRS-University of Strasbourg, Biotechnology and Cell Signaling, Illkirch, France/Strasbourg Drug Discovery and Development Institute (IMS), Institut de Science et D’Ingénierie Supramoléculaire, 67000 Strasbourg, FranceNeutron Therapy Research Center, Collaborative Research Center, Department of Cell Chemistry, Okayama University, Okayama 700-8558, JapanDepartment of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, ItalyCNRS-University of Strasbourg, Biotechnology and Cell Signaling, Illkirch, France/Strasbourg Drug Discovery and Development Institute (IMS), Institut de Science et D’Ingénierie Supramoléculaire, 67000 Strasbourg, FranceThe current therapies based on immunosuppressant or new biologic drugs often show some limitations in term of efficacy and applicability, mainly because of their inadequate targeting and of unwanted adverse reactions they generate. To overcome these inherent problems, in the last decades, innovative nanocarriers have been developed to encapsulate active molecules and offer novel promising strategies to efficiently modulate the immune system. This review provides an overview of how it is possible, exploiting the favorable features of nanocarriers, especially with regard to their immunogenicity, to improve the bioavailability of novel drugs that selectively target immune cells in the context of autoimmune disorders and inflammatory diseases. A focus is made on nanoparticles that selectively target neutrophils in inflammatory pathologies.https://www.mdpi.com/2073-4409/10/3/707therapeutic carriersnanoparticlesdrug targetingimmunomodulationneutrophilsNETosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Laura Talamini Eiji Matsuura Luisa De Cola Sylviane Muller |
spellingShingle |
Laura Talamini Eiji Matsuura Luisa De Cola Sylviane Muller Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases Cells therapeutic carriers nanoparticles drug targeting immunomodulation neutrophils NETosis |
author_facet |
Laura Talamini Eiji Matsuura Luisa De Cola Sylviane Muller |
author_sort |
Laura Talamini |
title |
Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases |
title_short |
Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases |
title_full |
Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases |
title_fullStr |
Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases |
title_full_unstemmed |
Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases |
title_sort |
immunologically inert nanostructures as selective therapeutic tools in inflammatory diseases |
publisher |
MDPI AG |
series |
Cells |
issn |
2073-4409 |
publishDate |
2021-03-01 |
description |
The current therapies based on immunosuppressant or new biologic drugs often show some limitations in term of efficacy and applicability, mainly because of their inadequate targeting and of unwanted adverse reactions they generate. To overcome these inherent problems, in the last decades, innovative nanocarriers have been developed to encapsulate active molecules and offer novel promising strategies to efficiently modulate the immune system. This review provides an overview of how it is possible, exploiting the favorable features of nanocarriers, especially with regard to their immunogenicity, to improve the bioavailability of novel drugs that selectively target immune cells in the context of autoimmune disorders and inflammatory diseases. A focus is made on nanoparticles that selectively target neutrophils in inflammatory pathologies. |
topic |
therapeutic carriers nanoparticles drug targeting immunomodulation neutrophils NETosis |
url |
https://www.mdpi.com/2073-4409/10/3/707 |
work_keys_str_mv |
AT lauratalamini immunologicallyinertnanostructuresasselectivetherapeutictoolsininflammatorydiseases AT eijimatsuura immunologicallyinertnanostructuresasselectivetherapeutictoolsininflammatorydiseases AT luisadecola immunologicallyinertnanostructuresasselectivetherapeutictoolsininflammatorydiseases AT sylvianemuller immunologicallyinertnanostructuresasselectivetherapeutictoolsininflammatorydiseases |
_version_ |
1724205511586349056 |